TP53 and cancer: On the other hand, the removal by CRISPR/Cas9 of p53 mutants with reported GOF - including p53Y220C - in diverse cancer cell lines had no significant impact on cell survival or proliferation, and the cell death caused by RNA interference against p53Y220C might result from nonspecific toxic effects (Wang et al., 2024).